Tuesday, July 21, 2026
← Back to archivePolicy
Policy•STAT News•Jul 20, 2026
HHS vaccine committee quietly gets new charter
background ▾
- •NVAC's charter has been rewritten to de-emphasize vaccines and promote alternative preventive measures including supplements and repurposed drugs, marking a substantive change in federal vaccine advisory policy under the Kennedy-led HHS
- •The committee composition is being restructured to exclude vaccine-research scientists with industry ties and expand public representation, potentially undermining scientific expertise in vaccine safety and efficacy deliberations
- •Monitor regulatory actions and funding decisions affecting vaccine development pipelines, as well as shifts in vaccine approval timelines and standards that may follow from NVAC's restructured advisory role
Policy•KFF•Jul 21, 2026
Guardrails for AI in Health Care — How High?
background ▾
- •Regulatory frameworks for clinical AI deployment remain under development with unclear governance authority across FDA, CMS, and other bodies
Policy•STAT News•Jul 21, 2026
Opinion: Science and the public are learning the wrong lessons from Covid
background ▾
- •Two high-profile academic studies claiming NPIs had minimal Covid mortality benefit contain critical methodological flaws that misframe the research question, risking permanent distortion of pandemic history.
- •Early NPIs (masks, distancing, closures) in 2020 likely prevented transmission and saved lives at a ratio of approximately one life per 150 infections prevented, based on contemporaneous research and field experience.
Policy•STAT News•Jul 21, 2026
Opinion: How a controversial rule could hurt the NIH’s ability to manage risk
background ▾
- •The proposed rule would allow termination of NIH grants if they no longer serve the President's policy priorities, fundamentally shifting grantmaking from merit-based to politically motivated criteria with finalization imminent.
- •The NIH has functioned as a de facto regulator of high-risk research (human-subject ethics, biosafety, genetic engineering) through soft power and researcher collaboration; politicization will erode this historical leverage and weaken science self-governance.
- •Watch for: finalization of the OMB rule by end of August; potential exodus of researchers from U.S. basic science; and erosion of NIH's ability to establish new biosafety/biosecurity frameworks for emerging technologies like synthetic biology and AI.
Policy•STAT News•Jul 21, 2026
THC drinks are sold beside sodas, iced tea, and even chocolate milk, often in violation of state laws
background ▾
- •THC beverages are being sold at concentrations 5-100x higher than New York's legal limit (1 mg/serving), often without age verification or clear labeling, in violation of state law
- •Pediatric emergency departments report 4-5 cases weekly of children ingesting THC drinks, with presentations including lethargy, confusion, nausea, vomiting, and altered mental status; 8-10% of high school seniors report hemp-derived cannabis product use
- •The regulatory loophole from the 2018 Farm Bill closes in November, but industry confidence and major retailer expansion (Target, Circle K, Sprouts) suggest regulatory workarounds are expected rather than genuine market contraction
TargetCircle KSproutsTHC (tetrahydrocannabinol)
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 20, 2026
Tempus buys out cancer genomics partner Personalis in $1.5 billion deal
background ▾
- •Tempus acquires full control of NeXT Personal MRD test, a liquid biopsy assay that detects circulating tumor DNA to monitor cancer treatment efficacy and recurrence—a high-growth market segment
- •Personalis demonstrated strong commercial momentum with Q2 2024 preliminary sales of $22.4M and 33% quarter-over-quarter growth in test volumes, validating market demand and reimbursement acceptance
- •Watch for: regulatory submissions/clearances for expanded MRD testing indications, payer coverage decisions and reimbursement rates, competitive responses from other liquid biopsy vendors (Guardant, Foundation, etc.), and integration of MRD data into Tempus' AI oncology platform
TempusPersonalisNeXT Personal
→ Read original articleMarket Access•Fierce Biotech•Jul 20, 2026
De-Risking a Rare Disease Launch Starts with Precision
background ▾
- •Only 61% of rare disease specialty prescriptions are approved and filled, with majority of patients discontinuing therapy within one year, representing significant value leakage for manufacturers
- •68% of rare disease stakeholders report delays in care coordination updates at critical moments, driven by fragmentation across disconnected pharmacy and clinical teams
- •Specialized rare disease pharmacy models with disease-state expertise, adaptive workflows, and individualized support are positioned as essential to de-risking rare disease commercialization and reducing avoidable patient drop-off
Market Access•Fierce Biotech•Jul 20, 2026
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
background ▾
- •Scribe's lead asset STX-1150 seeks to achieve PCSK9 inhibition with potentially decade-long dosing intervals versus Leqvio's semi-annual schedule, representing a significant clinical differentiation if proven efficacious
- •Phase 1 topline data for STX-1150 expected H1 2027 represents a near-term inflection point for the company's valuation and pipeline credibility
- •Watch for: Phase 1 LDL-C reduction data (H1 2027), clinical advancement of STX-1400 and STX-1200, and partnership progress with Sanofi and Eli Lilly; competitive pressure from established PCSK9 inhibitors and emerging GLP-1 therapies in cardiometabolic disease
Scribe TherapeuticsBiogenAmgenSTX-1150STX-1400STX-1200
→ Read original articleMarket Access•Fierce Biotech•Jul 20, 2026
BMS expands AI footprint with Nvidia, aiming for ‘most powerful AI factory in life sciences’
background ▾
- •BMS is building what it claims is the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences, representing a significant capital commitment to AI-driven R&D infrastructure.
- •The partnership reflects a broader industry trend toward hybrid intelligence models where AI co-scientists work alongside human researchers to improve decision-making and reduce manual work in drug development.
- •Monitor pipeline advancement and clinical trial success rates over the next 12-24 months to assess whether BMS's substantial AI infrastructure investments translate into improved R&D productivity and earlier-stage pipeline advancement.
Bristol Myers SquibbNvidiaAnthropic
→ Read original articleMarket Access•Endpoints News•Jul 20, 2026
UnitedHealth Group lays out progress in AI push
background ▾
- •UnitedHealth Group is actively deploying AI across its business following a major announced investment earlier in the year
UnitedHealth Group
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 20, 2026
Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trial
background ▾
- •TG-C missed both co-primary endpoints and all key secondary endpoints in the U.S. phase 3 trial, demonstrating no efficacy advantage over placebo at one year post-injection
- •A second phase 3 trial with nearly identical design and endpoints is reporting in October; Kolon's future development strategy depends entirely on that readout
- •Monitor October data release and Kolon's strategic decision; negative second trial result would likely end the program given consistent trial design
Kolon TissueGeneAmpio PharmaceuticalsCentrexion TherapeuticsTG-CCNTX-4975
→ Read original article